Most popular news headlines for Monday, August 11 2014

August 12, 2014

The most-clicked news item for Monday was “FDA Accepts First-Ever Biosimilar Application for Monoclonal Antibody.”  This piece from details how a South Korean drug manufacturer Celltrion has submitted a biosimilar application to the FDA for Remsima, which is biosimilar to Jannsen’s Remicade.

The second most popular item was Fierce Biotech’s “J&J's diabetes combo wins FDA nod in a fast-crowding space.”  JNJ’s new Invokamet, combines the SGLT2 blocker canagliflozin combined with metformin.

The third most-clicked news item was another Fierce Biotech piece  - this one about Sanofi’s agreement to commercialize MannKind’s inhaled insulin Afrezza.  Sanofi fills some big shoes in $925M Afrezza pact with MannKind” discusses the details of the agreement, including the $150 million upfront payment, as well as predictions for the success of the collaboration.

The fourth most-clicked news item was from Bloomberg News - “Exact Sciences Wins U.S. Approval for Colon Cancer Test.”  Cologuard is a non-invasive home DNA screening test that can be used to determine whether or not a colonoscopy is needed.  The test is also the first to go through the parallel review process with the FDA and the Centers for Medicare and Medicaid Services. 

CP Wire

Submit an article to cafepharma's CP Wire. Click here to find out more.

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.